The FDA has approved Roche's anemia drug Mircera, but don't look for any big new product launches soon. Last month Amgen won a patent infringement case [1] on the therapy. And Roche is studying its options--including a possible appeal of the case. In the meantime, Mircera is already available in a long lineup of countries that include Sweden, Germany and the UK.
- see Roche's release [2]
- read the AFX report [3] on Mircera
Related Articles:
Amgen wins patent fight with Roche. Report [1]
Roche: Patent ruling won't stop Mircera. Report [4]
Roche to Launch Mircera in U.K. and Germany. Report [5]
FDA wants more data on new Aranesp doses. Report [6]
Links:
[1] http://www.fiercepharma.com/story/amgen-wins-patent-fight-with-roche/2007-10-24?utm_medium=nl&utm_source=link
[2] http://www.fiercebiotech.com/press-releases/press-release-fda-approves-mircera-first-renal-anemia-treatment-us-monthly-maintenanc
[3] http://money.cnn.com/news/newsfeeds/articles/newstex/AFX-0013-20997169.htm
[4] http://www.fiercepharma.com/story/roche-patent-ruling-stop-mircera/2007-08-29
[5] http://www.fiercepharma.com/story/roche-launch-mircera-u-k-and-germany/2007-08-02
[6] http://www.fiercebiotech.com/story/fda-wants-more-data-on-new-aranesp-doses/2006-10-16